Teva’s AJOVY shows promising results in migraine prevention Phase IV study

By on    Pharma Industry News  

Teva’s AJOVY shows promising results in migraine prevention Phase IV study

New interim analysis from the pan-European PEARL Phase IV study reveals that Teva Pharmaceutical Industries’ AJOVY (fremanezumab) has led to a significant reduction in monthly migraine days for almost 60% of patients. The migraine prevention drug also showed sustained improvement in disability scores and acute medication use over 12 months. The data further show that […]

Teva secures FDA approval for Ajovy injection in migraine prevention

By on    Pharma Industry News  

Teva secures FDA approval for Ajovy injection in migraine prevention

Teva Pharmaceutical Industries has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving Ajovy (fremanezumab-vfrm) injection for migraine prevention in adults. The approval marks a pivotal advancement in migraine care, positioning Ajovy as the first anti-calcitonin gene-related peptide (CGRP) treatment approved in the United States with both quarterly (675 mg) […]